U-Iowa physician suggests possible enzyme deficiency in cystic fibrosis

June 24, 2003

IOWA CITY, Iowa -- Mucus that excessively accumulates in the lungs of patients with cystic fibrosis (CF) may be linked to the deficiency of an enzyme called arylsulfatase B. The deficiency may in turn be linked to the known genetic mutation in CF -- a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The possible connection is proposed by Joanne Tobacman, M.D., University of Iowa assistant professor (clinical) of internal medicine, who reviewed 30 years of research about the enzyme and chemicals it normally metabolizes, or processes for use by the body. Tobacman's opinion article appears in the June 6 issue of CHEST: The Cardiopulmonary and Critical Care Journal of the American College of Chest Physicians.

"The CFTR gene is mutated in people with CF but the observed manifestations of the disease have not been fully explained by that genetic change," Tobacman said. "Mutations in the CFTR gene might reduce the arylsulfatase B activity."

The CFTR defect is known to alter a protein, causing problems in cellular channels that normally regulate salt and water secretions. The defective CFTR protein also affects other cellular processes. The first CFTR gene discovery was made in 1989. Tobacman drew on an even earlier observation by another researcher to draw a possible connection between CFTR and arylsulfatase B.

In 1970, Elizabeth Neufeld, Ph.D., formerly a researcher with the National Institutes of Health (now professor and chair of biological chemistry at the University of California at Los Angeles), found diminished sulfatase enzyme activity in the lymphoid cells lines of patients with CF.

Normally, arylsulfatase B metabolizes two sugar chains called dermatan sulfate and chondroitin-4 sulfate. However, when arylsulfatase B is absent or insufficient, these substances can build up and change the characteristics of secretions.

"These sulfated glycosaminoglycans, or GAGs can accumulate, altering the properties of secretions and making it more difficult to clear them," Tobacman said. "This predisposes people with CF to chronic infection."

Pseudomonas, a bacteria that often infects people with CF, makes sulfatase and may utilize the GAGs that are not metabolized because of insufficient arylsulfatase B. Thus, the extra GAGs may help this bacteria flourish.

Tobacman also noted that CF shares a few clinical characteristics with the recessive genetic disease Maroteaux-Lamy Syndrome, which is caused by complete or severe arylsulfatase B deficiency.

The article is accompanied by an editorial by Bruce Rubin, M.D., professor of pediatrics, medicine, medical engineering, physiology and pharmacology at Wake Forest University School of Medicine. Rubin writes, "CFTR is a large and complex channel, so it is not surprising that it would have diverse functions. The link between these functions of CFTR and CF disease remains a matter of speculation and debate."

The next step for Tobacman and colleagues will be to assess the impact of CFTR gene transfection on arylsulfatase B activity in CF cell lines. Transfection involves introducing a functional copy of the gene. Tobacman also will further explore the effect of sulfatase enzymes in clinical conditions. The chemical name of arylsulfatase B is N-acetylgalactosamine-4-sulfatase.

University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at www.uihealthcare.com.
-end-
ABSTRACT: The abstract of Dr. Joanne Tobacman's article, "Does Deficiency of Arylsulfatase B Have a Role in Cystic Fibrois?" (Chest. 2003;123:2130-2139) is at http://www.chestjournal.org/cgi/content/abstract/123/6/2130. It also is provided below:

Does Deficiency of Arylsulfatase B Have a Role in Cystic Fibrosis? Joanne K. Tobacman, MD
From the Department of Internal Medicine, University of Iowa Health Care, Iowa City, IA.

Cystic fibrosis (CF) is associated with mutation and abnormal function of the cystic fibrosis transmembrane conductance regulator (CFTR) that affects cellular chloride transport. Clinically, CF of the lung is associated with excessive accumulation of secretions, including the sulfated glycosaminoglycans, chondroitin sulfate and dermatan sulfate (DS), both of which contain sulfated N-acetylgalactosamine residues. The sulfatase enzymes, which are a highly conserved group of enzymes with high specificity for designated sulfate groups, include arylsulfatase B, a lysosomal enzyme. Arylsulfatase B, also known as N-acetyl galactosamine 4-sulfatase, can degrade DS and chondroitin-4 sulfate. Previously reported data demonstrated diminished activity of arylsulfatase B in lymphoid cell lines of patients with CF compared to normal control subjects. Frequent infections with Pseudomonas, a sulfatase-producing organism, occur in patients with CF, whereas infections with Mycobacterium tuberculosis, which lacks sulfatase activity, are infrequent. Additional investigation to determine if diminished function of arylsulfatase B is a consistent finding in cells of patients with CF may be informative, and may help to correlate the molecular, biochemical, and clinical characteristics of CF.

University of Iowa

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.